Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04398329
PHASE1/PHASE2

Dose-Escalation Study of HTX-034 Following Bunionectomy

Sponsor: Heron Therapeutics

View on ClinicalTrials.gov

Summary

This was a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b evaluated escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 was a dose-expansion phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase 1b, compared with bupivacaine HCl.

Official title: A Phase 1b/2, Randomized, Blinded, Active-Controlled Study of Escalating Doses of HTX-034 for Postoperative Analgesia in Subjects Undergoing Unilateral, First Metatarsal Bunionectomy With Osteotomy and Internal Fixation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

78

Start Date

2020-05-08

Completion Date

2021-07-15

Last Updated

2026-06-09

Healthy Volunteers

No

Interventions

DRUG

HTX-034 low dose

HTX-034 (bupivacaine/aprepitant/meloxicam) fixed dose: 21.7 mg/4.3 mg/0.6 mg

DRUG

HTX-034 high dose

HTX-034 (bupivacaine/aprepitant/meloxicam) individualized dose: 30.6 mg/6.1 mg/0.9 mg to 51.5 mg/10.3 mg/1.5 mg

DEVICE

Luer lock applicator

Applicator for instillation

DRUG

Bupivacaine HCl

Bupivacaine HCl 50 mg

Locations (4)

Arizona Research Center

Phoenix, Arizona, United States

First Surgical Hospital

Bellaire, Texas, United States

Endeavor Clinical Trials, LLC

San Antonio, Texas, United States

JBR Clinical Research

Salt Lake City, Utah, United States